

2018 年度

Satake.H, Sagawa.T, Fujikawa.K, Hatachi.Y, Yasui.H, Kotaka.M, Kato.T, Tsuji.A

A phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane

Cancer Chemotherapy and Pharmacology: 2018 Nov; 82(5):839-845

Satake.H, Sunakawa.Y, Miyamoto.Y, Nakamura.M, Nakayama.H, Shiozawa.M, Makiyama.A, Kobayashi.K, Kubota.Y, Mori.M, Kotaka.M, Takagane.A, Gotoh.M, Takeuchi.M, Fujii.M, Ichikawa.W, Sekikawa.T

A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11

Oncotarget: 2018 :vol. 9 (27): 18811-18820

Hironaga Satake, Akihito Tsuji, Masato Nakamura, Masaaki Ogawa, Takeshi Kotake, Yukimasa Hatachi, Hisateru Yasui, Akinori Takagane, Yoshihiro Okita, Kumi Nakamura, Toshihide Onikubo, Masahiro Takeuchi, Masashi Fujii

Phase I Study of Primary Treatment with 5-FU, Oxaliplatin, Irinotecan, Levofolinate, and Panitumumab Combination Chemotherapy in Patients with Advanced/Recurrent Colorectal Cancer Involving the Wild-type RAS Gene: the JACCRO CC-14 Study

International Journal of Clinical Oncology: 2018: vol.23 (3): 490-496

Ogata. T, Satake. H, Ogata. M, Hatachi. Y, Yasui. H

Hyperprogressive Disease in the Irradiation Field after a Single Dose of Nivolumab for Gastric Cancer: A Case Report

Case Rep Oncol: 2018: vol. 11(1) : 143-150

Ogata. T, Satake. H, Ogata. M, Hatachi. Y, Inoue. K, Hamada. M, Yasui. H

Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: a retrospective study

Oncotarget: 2018 Oct: 10(13):528-531.

Tsuchihashi K, Ito M, Moriwaki T, Fukuoka S, Taniguchi H, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama A, Denda T, Satake H, Suto T, Sugimoto N, Katsumata K, Ishikawa T, Kashiwada T, Oki E, Komatsu Y, Okuyama H, Sakai D, Ueno H, Tamura T, Yamashita K, Kishimoto J, Shimada Y, Baba E.

Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer.

Clin Colorectal Cancer. 2018 Jul 29. pii: S1533-0028(18)30206-8

Iwamoto S, Ooki A, Morita S, Hara H, Tanioka H, Satake H, Kataoka M, Kotaka M, Kagawa Y, Nakamura M, Shingai T, Ishikawa M, Miyake Y, Sudo T, Hashiguchi Y, Yabuno T, Sakamoto J, Tsuji A, Ando M, Yamaguchi K.

A prospective Phase II study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK trial.

Cancer Med. 2018 Jul 26.

Kotake T, Satake H, Okita Y, Hatachi Y, Hamada M, Omiya M, Yasui H, Hashida T, Kaihara S, Inokuma T, Tsuji A.

Prevalence and risk factors of hepatitis B virus reactivation in patients with solid tumors with resolved HBV infection.

Asia Pac J Clin Oncol. 2018 Jul 8.

Yanagimoto H, Toyokawa H, Sakai D, Wada H, Satoi S, Yamamoto T, Nagano H, Toyoda M, Ajiki T, Satake H, Tsuji A, Miyamoto A, Tsujie M, Takemura S, Yanagihara K, Ioka T.

A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1202).

Cancer Chemother Pharmacol. 2018 Mar;81(3):461-468

Yabushita T, Satake H, Maruoka H, Morita M, Katoh D, Shimomura Y, Yoshioka S, Morimoto T, Ishikawa T.

Expression of multiple leukemic stem cell markers is associated with poor prognosis in de novo acute myeloid leukemia.

Leuk Lymphoma. 2018 Sep;59(9):2144-2151.

Kobayashi S, Nagano H, Tomokuni A, Gotoh K, Sakai D, Hatano E, Seo S, Terajima H, Uchida Y, Ajiki T, Satake H, Kamei K, Tohyama T, Hirose T, Ikai I, Morita S, Ioka T; Kansai Hepato-Biliary Oncology (KHBO) Group.

A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group.
Ann Surg. 2018 Oct 17. doi: 10.1097/SLA.0000000000002865 [Epub ahead of print]

Ogata T, Kikawa Y, Ogata M, Satake H, Hatachi Y, Yasui H.
Acute Liver Failure with Diffuse Liver Metastasis from Breast Cancer, Not Detected by Computed Tomography: 2 Case Reports.
Case reports in oncology. 2018 Oct;11(3):699-704.

Saeki H, Oki E, Kashiwada T, Arigami T, Makiyama A, Iwatsuki M, Narita Y, Satake H, Matsuda Y, Sonoda H, Shimokawa M, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC).
Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).
European Journal of Cancer. 2018 Dec;41-49.

Sunakawa Y, Satake H, Ichikawa W.
Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors.
World J Gastrointest Oncol. 2018 Dec 15;10(12):528-531.

Kikawa Y, Hatachi Y, Rumpold G, Tokiwa M, Takebe S, Ogata T, Satake H, Kato H, Tsuji A, Yasui H, Holzner B.
Evaluation of health-related quality of life via the Computer-Based Health Evaluation System (CHES) for Japanese metastatic breast cancer patients: a single-center pilot study.
Breast Cancer. 2019 Mar;26(2):255-259

Takatsugu Ogata, Hironaga Satake, Misato Ogata, Yukimasa Hatachi, Hayato Maruoka, Daisuke Yamashita, Hiroki Hashida, Madoka Hamada and Hisateru Yasui
Safety and effectiveness of FOLFOXIRI plus molecular target drug therapy for metastatic colorectal cancer: A multicenter retrospective study
Oncotarget. 2019 Feb 1;10(10):1070-1084

Misato Ogata , Yukimasa Hatachi , Takatsugu Ogata , Hironaga Satake ,Yukihiro Imai and Hisateru Yasui
Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation: A Case Report
Intern Med. 2019 Apr 1;58(7):1029-1032.

Satake H, Sunakawa Y, Miyamoto Y, Nakamura M, Nakayama H, Shiozawa M, Makiyama A, Kobayashi K, Kubota Y, Mori M, Kotaka M, Takagane A, Gotoh M, Takeuchi M, Fujii M, Ichikawa W, Sekikawa T.

Correction: A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11.

Oncotarget, 2018. 30023

Ogata T, Satake H, Ogata M, Hatachi Y, Maruoka H, Yamashita D, Hashida H, Hamada M, Yasui H.

Safety and effectiveness of FOLFOXIRI plus molecular target drug therapy for metastatic colorectal cancer: A multicenter retrospective study.

Oncotarget, 2018. 10(10):1070-1084

佐竹悠良

1章 がん治療で起こる合併症/副作用の病態と実臨床での具体的対処法

タイトル：16節 減量

がん治療で起こる副作用・合併症の治療法と薬剤開発 株式会社技術情報協会